Piper Sandler says Ocular Therapeutix at its investor day provided a positive update on patient enrollment for SOL-1 in which it appears to be tracking ahead of its projected timelines of the first half of 2025. SOL-1 could complete enrollment by Q4 and Ocular also reiterated its stats assumptions, which “has good odds of winning,” the analyst tells investors in a research note. The firm keeps an Overweight rating on the shares with a $15 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix Shareholders Approve Expansion and Leadership Changes
- Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
- Ocular Therapeutix to hold investor day
- Adverum Biotechnologies appoints Ozden as CMO, Kiss to board of directors
- Ocular Therapeutix® to Host Investor Day on June 13, 2024